BioCentury | Oct 15, 2012
Strategy

At home with Servier

...strontium formulation in Phase II testing. The company licensed ex-U.S. rights to the compound from Osteologix...
...Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), South San Francisco, Calif. Osteologix...
BioCentury | Nov 14, 2011
Company News

AmpliPhi BioSciences management update

...Autoimmune, Gene/Cell therapy Hired: Philip Young as president and CEO, formerly president and CEO of Osteologix Inc. WIR...
BioCentury | Aug 15, 2011
Company News

Osteologix musculoskeletal news

...operations in Ireland. Parent company Osteologix Inc. has been dissolved and former shareholders received shares of Osteologix...
...Servier (Neuilly-sur-Seine, France) and continuing to seek U.S. development partners for the compound. Last year, Osteologix...
...osteoporosis and is in preclinical testing to treat osteoarthritis and osteonecrosis. At Sept. 30, 2010, Osteologix Inc....
BioCentury | Dec 20, 2010
Company News

Osteologix musculoskeletal news

...At Sept. 30, Osteologix had $4.1 million in cash and nine-month operating gain of $836,000. Osteologix's...
...treat osteoporosis. The strontium formulation is also in preclinical testing to treat osteoarthritis and osteonecrosis. Osteologix Inc....
BioCentury | Aug 9, 2010
Company News

Osteologix, Servier deal

...is a strontium formulation which completed a Phase II trial to treat osteoporosis in 2007. Osteologix...
...Japan. Servier will be responsible for all ex-U.S. development costs (see BioCentury, Nov. 12, 2007). Osteologix Inc....
BioCentury | Jan 11, 2010
Financial News

Osteologix completes private placement

Osteologix Inc. (OTCBB:OLGX), San Francisco, Calif. Business: Musculoskeletal Date completed: 1/4/10 Type: Private placement Raised: $1 million Shares: 2 million Price: $0.50 Shares after offering: 31.5 million Investor: Nordic Biotech Opportunity Fund WIR Staff Musculoskeletal...
BioCentury | Jul 7, 2008
Finance

1H08 warrant coverage

...AMEX:NBS) (A) $1.20 (unit) $0.96 NA 146% $0.9 ONI (AMEX:ONI) $0.45 $0.49 -8% 290% $2.6 Osteologix...
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech board of directors update

...Neuro-Hitech Inc. (OTCBB:NHPI), New York, N.Y. Business: Neurology Appointed: Phillip Young, president and CEO of Osteologix Inc....
BioCentury | May 19, 2008
Clinical News

NB S101: Phase III start

...year, Osteologix will begin a Phase III trial of oral NB S101 given once daily. Osteologix Inc....
BioCentury | Apr 7, 2008
Company News

Neurobiological management update

...Technologies Inc. (NASDAQ:NTII), Emeryville, Calif. Business: Neurology Hired: Matthew Loar as CFO, formerly CFO of Osteologix Inc. WIR...
Items per page:
1 - 10 of 31
BioCentury | Oct 15, 2012
Strategy

At home with Servier

...strontium formulation in Phase II testing. The company licensed ex-U.S. rights to the compound from Osteologix...
...Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), South San Francisco, Calif. Osteologix...
BioCentury | Nov 14, 2011
Company News

AmpliPhi BioSciences management update

...Autoimmune, Gene/Cell therapy Hired: Philip Young as president and CEO, formerly president and CEO of Osteologix Inc. WIR...
BioCentury | Aug 15, 2011
Company News

Osteologix musculoskeletal news

...operations in Ireland. Parent company Osteologix Inc. has been dissolved and former shareholders received shares of Osteologix...
...Servier (Neuilly-sur-Seine, France) and continuing to seek U.S. development partners for the compound. Last year, Osteologix...
...osteoporosis and is in preclinical testing to treat osteoarthritis and osteonecrosis. At Sept. 30, 2010, Osteologix Inc....
BioCentury | Dec 20, 2010
Company News

Osteologix musculoskeletal news

...At Sept. 30, Osteologix had $4.1 million in cash and nine-month operating gain of $836,000. Osteologix's...
...treat osteoporosis. The strontium formulation is also in preclinical testing to treat osteoarthritis and osteonecrosis. Osteologix Inc....
BioCentury | Aug 9, 2010
Company News

Osteologix, Servier deal

...is a strontium formulation which completed a Phase II trial to treat osteoporosis in 2007. Osteologix...
...Japan. Servier will be responsible for all ex-U.S. development costs (see BioCentury, Nov. 12, 2007). Osteologix Inc....
BioCentury | Jan 11, 2010
Financial News

Osteologix completes private placement

Osteologix Inc. (OTCBB:OLGX), San Francisco, Calif. Business: Musculoskeletal Date completed: 1/4/10 Type: Private placement Raised: $1 million Shares: 2 million Price: $0.50 Shares after offering: 31.5 million Investor: Nordic Biotech Opportunity Fund WIR Staff Musculoskeletal...
BioCentury | Jul 7, 2008
Finance

1H08 warrant coverage

...AMEX:NBS) (A) $1.20 (unit) $0.96 NA 146% $0.9 ONI (AMEX:ONI) $0.45 $0.49 -8% 290% $2.6 Osteologix...
BioCentury | Jun 16, 2008
Company News

Neuro-Hitech board of directors update

...Neuro-Hitech Inc. (OTCBB:NHPI), New York, N.Y. Business: Neurology Appointed: Phillip Young, president and CEO of Osteologix Inc....
BioCentury | May 19, 2008
Clinical News

NB S101: Phase III start

...year, Osteologix will begin a Phase III trial of oral NB S101 given once daily. Osteologix Inc....
BioCentury | Apr 7, 2008
Company News

Neurobiological management update

...Technologies Inc. (NASDAQ:NTII), Emeryville, Calif. Business: Neurology Hired: Matthew Loar as CFO, formerly CFO of Osteologix Inc. WIR...
Items per page:
1 - 10 of 31